NCT03885739

Continuous Pericapsular Nerve Group Block in Hip Fracture Patients

Completed NA Last updated 15 May 2023

What this trial tests

NA trial testing Continuous Pericapsular Nerve Group block in Hip Fractures in 15 participants. Completed in 15 January 2019.

Timeline

1 October 2018

Primary endpoint
15 January 2019

15 January 2019

Quick facts

Lead sponsor	Adriana Margarita Cadavid
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 October 2018
Primary completion	15 January 2019
Estimated completion	15 January 2019
Sites	1 location across Colombia

Drugs / interventions tested

• Continuous Pericapsular Nerve Group block

Conditions studied

• Hip Fractures — all drugs for Hip Fractures →

Sponsor

Adriana Margarita Cadavid

Who can join

Adults 18 to 95, any sex, with Hip Fractures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background- Despite clinical guidelines favoring surgical repair of hip fracture (HF) within 48 hours of injury, patients may wait considerable periods of time for their turn in the operating room. In this context, continuous nerve blocks are an attractive alternative for pain management. However, the ideal block technique is not yet defined. Recently a new ultrasound-guided approach for selective blockade of the articular branches to the hip, the PENG (Pericapsular Nerve Group) block, has been proposed with potentials advantages for perioperative hip fracture analgesia.

Objective- To describe the analgesic efficacy and feasibility of continuous Pericapsular Nerve Group block (CPENGB) in patients with HF.

Design-Interventional study. Setting-Academic Level 3 center. Methods- Two experienced anesthesiologist completed 15 sonographically guided Pericapsular Nerve Group (PENG) injections and catheter insertion in patients with severe pain awaiting HF surgery. Each injection consisted of 20 mL of local anesthetics followed by a 0.1% bupivacaine continuous infusion at a constant rate of 8 ml per hour. Pain at rest and on 15° leg lift of the fractured leg were assessed before procedure, 10 and 30 minutes after block performance, and each 24 hours until surgery. A reduction of severe or moderate dynamic pain to mild pain or no pain, and a pain relief of 2 (moderate) were clinically significant findings. To determine feasibility time and number of attempts to perform the procedure were measured.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.